Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia - Pitt, Bertram, MD; Anker, Stefan D., MD, PhD; Lund, Lars H., MD, PhD; Coats, Andrew J.S., MD; Filippatos, Gerasimos, MD; Rossignol, Patrick, MD, PhD; Weir, Matthew R., MD; Friede, Tim; Kosiborod, Mikhail N., MD; Metra, Marco; Böhm, Michael, MD; Ezekowitz, Justin A., MBBCh, MSc; et al. (Journal of the American College of Cardiology, 2024)
Keywords: Aged; Angiotensin Receptor Antagonists - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Cardiovascular; Female; Heart failure; Heart Failure - drug therapy; Humans; Hyperkalemia; Hyperkalemia - blood; Hyperkalemia - drug therapy; Life Sciences; Male; Middle Aged; Mineralocorticoid receptor antagonists; Mineralocorticoid Receptor Antagonists - therapeutic use; Patiromer; Polymers - therapeutic use; Renin-Angiotensin System - drug effects; renin–angiotensin system inhibitors; Stroke Volume - drug effects; eGFR; heart failure; HK; potassium; estimated glomerular filtration rate; RAS; hyperkalemia; renin–angiotensin system inhibitors; patiromer; K; mineralocorticoid receptor antagonist; HFrEF; renin–angiotensin system; mineralocorticoid receptor antagonists; heart failure with reduced ejection fraction; MRA